2025-05-13
Weight loss drugs are squeezing the food industry
The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s loss.
[...]Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-01-10
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
2025-04-23
Eli Lilly is stepping up its fight against copycat weight-loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss dr [...]
2025-05-30
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
2025-05-20
Noom is offering microdoses of compounded Wegovy for weight loss
Noom will start offering microdoses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health company continues to adapt to the growing demand for affordable weight-loss solu [...]
2025-10-24
Mistral launches its own AI Studio for quick development with its European open source, proprietary models
The next big trend in AI providers appears to be "studio" environments on the web that allow users to spin up agents and AI applications within minutes. Case in point, today the well-funded [...]
2025-05-07
Weight Watchers files for bankruptcy amid refocus on GLP-1 drugs
WeightWatchers (WW) announced Tuesday that it is filing for bankruptcy in an attempt to crawl out of more than $1 billion in debt. The news comes as the company is amid a refocus on prescribing weight [...]